[HTML] nature.com

[HTML][HTML] Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific Reports, 2022 - nature.com
Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …
被引用次数：23 相关文章

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - pubmed.ncbi.nlm.nih.gov
Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …
[PDF] researchgate.net

[PDF][PDF] Co‑occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non‑small cell lung cancer

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - researchgate.net
Results Patient demographics. Of the 458 patients with NSCLC whose tumors harbored
EGFR-activating mutation, 332 patients received EGFR TKIs and complete follow-up data …

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - mahidol.elsevierpure.com
Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - ui.adsabs.harvard.edu
Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - search.ebscohost.com
Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …
[HTML] nih.gov

[HTML][HTML] Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - ncbi.nlm.nih.gov
Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …
[PDF] academia.edu

[PDF][PDF] Co‑occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non‑small cell lung cancer

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - academia.edu
Results Patient demographics. Of the 458 patients with NSCLC whose tumors harbored
EGFR-activating mutation, 332 patients received EGFR TKIs and complete follow-up data …

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - europepmc.org
Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …

Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer.

P Sitthideatphaiboon, C Teerapakpinyo… - Scientific …, 2022 - europepmc.org
Despite the development of predictive biomarkers to shape treatment paradigms and
outcomes, de novo EGFR TKI resistance advanced non-small cell lung cancer (NSCLC) …